Canadian Cancer Trials Group Bulletins

Trial Management Group

Trial Activation

Canadian Cancer Trials Group Trial CO.23 -- A Phase III Randomized Study of BBI608 and Best Supportive Care versus Placebo and Best Supportive Care in Patients with Pretreated Advanced Colorectal Carcinoma -- was activated on April 15, 2013.

The primary objective of this trial is to compare overall survival, defined as the time from randomization until death from any cause, in patients with pre-treated advanced colorectal carcinoma treated with BBI608 plus best supportive care versus placebo plus best supportive care.

The target sample size is 650 patients.